Verona Pharma Share Discussion Threads

[timbo003] 27/6/2016 22:50

I managed to get partial answers to your questions Corbs. I'll include them in my notes which I will write up tomorrow

[corbine] 27/6/2016 08:12

thanks shakin
can u ask them when they do pfts during trilas why they dont do more than just fev1? can they also do dlco and the full range of pfts?
the equip is set up to do so at singhs place
thanks
corbs:-)

[timbo003] 27/6/2016 07:33

Shakin

From a US perspective, assets priced in £s (for example Verona shares) now look to be over 10% cheaper than they were this time last week. Furthermore assuming Verona manage to successfully execute their plans their earnings will be predominantly in US dollars, and earnings forecasts (in £s) will have risen 10% since this time last week.

It's the AGM this morning, so I will go along to that and report back later.

[shakin not stirred] 25/6/2016 02:03

Will us leaving the European union give us greater scope for an Asian pharmaceutical or an American pharma to purchase us outright or enter into a partnership deal with us. Hope someone can put this question to the board at the AGM and report back. Interested to hear if they feel this could have a positive benefit to the future of gaining significant share holder value or no real ramifications to the future. Does it hamper our fund raising ability especially this 44 million.

[joeblogg2] 24/6/2016 09:33

now they will:)

[joeblogg2] 24/6/2016 09:32

Marked down but the mm will not sell even 5k shares to me. How can this be fair!!!

[shakin not stirred] 21/6/2016 23:30

Pieces of the jigsaw are falling into place by design.

[joeblogg2] 21/6/2016 08:41

Looking very strong!!!

[senor_sensible] 20/6/2016 14:34

10 bagger!!! sounds good to me

[aishah] 20/6/2016 14:05

Funding secured for Phase IIb trial
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory
disease. Over the last two years’ VRP has reported positive outcomes from a five
stage Phase I/IIa programme which has de-risked RPL554 significantly. This drug
has been shown to have strong bronchodilatory and anti-inflammatory effects
with minimal side effects. New funds will support a broad programme of Phase II
trials for maintenance therapy via a nebulizer and hospital use. It will certainly
attract the attention of the drug majors. Median prices paid for PhaseII respiratory assets have headline valuations of $285m (£190m), equivalent to 19p per share.

[senor_sensible] 20/6/2016 13:24

hardman will be tweeting later.

[meijiman] 20/6/2016 09:30

Agree Joe-participants in the Placing will do so on a longer term strategic vision of where the company might get to if all goes well.Without knowing the level of oversubscription its difficult to judge the likely strength of the aftermarket.

[vasilis] 20/6/2016 09:23

The RNS is quite clear but there is a change in clinical priorities as outlined by JAK :-

"The funds raised from the Placing will allow the Company to focus on
conducting a comprehensive Phase 2b clinical trial programme for nebulised
RPL554 as a potential treatment for patients with COPD. We will also explore in
the clinic for the first time the use of RPL554 as a novel treatment for cystic
fibrosis expanding the potential of the drug into another respiratory disease
where there remains a significant unmet need. This follows on from the
compelling data we have generated in translational, preclinical models of this
disease."

Asthma is not now currently part of this 'focus'. There is an unambiguous emphasis on COPD and CF where there are clear unmet clinical needs. I suspect that the due diligence done by the new investors may have something to do with this sharper commercial focus as they also appear to have required non-execs to go on VRP's Board as part of their investment commitments.

The fact that existing and new institutional investors have soaked up the quite substantial placing on an oversubscribed basis after what seems fairly stringent due diligence, is a very positive sign. And whilst this of course means that PIs are therefore not included - there is the positive aspect that the IIs did not get their allocations at 'giveaway prices'. Plus the fact that the placing was oversubscribed means that the market will also see this as a positive development and help to gradually re-float the share price to higher levels.

One point regarding this statement :-

'The Company has undertaken to use commercially reasonable efforts to
procure a listing on NASDAQ and raise a further tranche of funding in the
future.'

This will both raise the profile of VRP - something also required by the new IIs ? - and provide new avenues for any future funding.

All in all, there does now seem to be a clear roadmap showing the way ahead on both the clinical and commercial fronts with strong II backing and the funds to match. VRP is definitely morphing into a more 'focused' and strategic company.

[joeblogg2] 20/6/2016 09:19

no meij. I can't see these institutions making a small turn here as they would not have stumped so much and also over subscribed!!

[meijiman] 20/6/2016 09:15

Maybe -but after the Placing stock is issued can hardly see it being tight. Plus the usual institutional buying will dry up for a good while.

[joeblogg2] 20/6/2016 09:08

All the recent good news was lost due to funding concerns, should be back above 4p+ soon and these backers will be looking for a lot, lot more so stock will become tight!!

[senor_sensible] 20/6/2016 08:54

illustrious backers have probably had a bit more meat on the bone than the PI gets to see in the RNS. IMO follow the big money, raising 44 mil and being oversubscribed in current investing climate speaks volumes.
Yep existing PIS have been diluted, but the company has an additional 44mil. So they get a smaller share of a bigger company. strong BUY IMO

[joeblogg2] 20/6/2016 08:44

PI's not participating as they have as timbo says illustrious backers now!!

[meijiman] 20/6/2016 08:40

Yes its all very positive. On the other hand unless you get stock in the placing you are being diluted. Are PIs being offfered new shares?

[senor_sensible] 20/6/2016 08:37

market seems to like the fact they have raised this money so easy....looking good.

[joeblogg2] 18/6/2016 12:06

For once even timbo not privy to the pacing because vrp have been backed my major/respected institutions.

[timbo003] 18/6/2016 08:59

That after hours announcement came out of the blue

I think most ordinary PIs were expecting a larger discount, less cash raised and a less illustrious cluster of placing participants. so on that basis the news should be well received by the market on Monday and now there's a lot more questions to ask at the AGM on Monday 27th.